Literature DB >> 21556879

LGI1 related limbic encephalitis and response to immunosuppressive therapy.

Bahar Kaymakamzade, Tülay Kansu, Ersin Tan, Neşe Dericioğlu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21556879     DOI： 10.1007/s00415-011-6044-7

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  7 in total

1.  Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.

Authors:  Meizan Lai; Maartje G M Huijbers; Eric Lancaster; Francesc Graus; Luis Bataller; Rita Balice-Gordon; John K Cowell; Josep Dalmau
Journal:  Lancet Neurol       Date:  2010-06-28       Impact factor: 44.182

2.  Improvement of non-paraneoplastic voltage-gated potassium channel antibody-associated limbic encephalitis without immunosuppressive therapy.

Authors:  Heidemarie Gast; Kaspar Schindler; Werner J Z'graggen; Christian W Hess
Journal:  Epilepsy Behav       Date:  2010-02-16       Impact factor: 2.937

Review 3.  Update on paraneoplastic neurological syndromes.

Authors:  Adrien Didelot; Jérôme Honnorat
Journal:  Curr Opin Oncol       Date:  2009-11       Impact factor: 3.645

4.  Potassium channel antibodies in two patients with reversible limbic encephalitis.

Authors:  C Buckley; J Oger; L Clover; E Tüzün; K Carpenter; M Jackson; A Vincent
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

5.  An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis.

Authors:  S H Wong; M D Saunders; A J Larner; K Das; I K Hart
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-26       Impact factor: 10.154

6.  Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody.

Authors:  M J Thieben; V A Lennon; B F Boeve; A J Aksamit; M Keegan; S Vernino
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

7.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.

Authors:  Angela Vincent; Camilla Buckley; Jonathan M Schott; Ian Baker; Bonnie-Kate Dewar; Niels Detert; Linda Clover; Abigail Parkinson; Christian G Bien; Salah Omer; Bethan Lang; Martin N Rossor; Jackie Palace
Journal:  Brain       Date:  2004-02-11       Impact factor: 13.501
  7 in total
  5 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  LGI-1-positive limbic encephalitis: a clinicopathological study.

Authors:  Jörg Schultze-Amberger; Debora Pehl; Werner Stenzel
Journal:  J Neurol       Date:  2012-05-31       Impact factor: 4.849

Review 3.  Antibodies in epilepsy.

Authors:  Cynthia M Correll
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

4.  Facio-brachio-crural dystonic episodes and drop attacks due to leucine rich glioma inactivated 1 encephalitis in two elderly Indian women.

Authors:  Boby Varkey Maramattom; Sachin Rajashekar Jeevanagi; Celinamma George
Journal:  Ann Indian Acad Neurol       Date:  2013-10       Impact factor: 1.383

5.  Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review.

Authors:  Yuou Teng; Ting Li; Zhizhong Yang; Mingwan Su; Jingnian Ni; Mingqing Wei; Jing Shi; Jinzhou Tian
Journal:  Front Neurol       Date:  2022-01-12       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.